camsirubicin + pegfilgrastim

**Camsirubicin + pegfilgrastim** is a combination investigational therapy under clinical development for the treatment of advanced soft tissue sarcoma. **Camsirubicin** is a proprietary analog of doxorubicin, designed to maintain antitumor activity with reduced risk of irreversible cardiotoxicity. **Pegfilgrastim**, a long-acting granulocyte colony-stimulating factor (G-CSF), is used prophylactically to mitigate neutropenia associated with chemotherapy. The combination aims to enable higher cumulative doses of camsirubicin by preventing dose-limiting neutropenia, allowing potential enhancement of antitumor efficacy without the typical cumulative heart damage seen with doxorubicin[1][2][3][5][6]. The regimen is administered as intravenous camsirubicin (once every 21 days for 6+ cycles) followed by subcutaneous pegfilgrastim (single dose within 24–96 hours after each cycle)[3][6]. Monopar Therapeutics is developing this combination for patients with advanced or metastatic soft tissue sarcoma, particularly those ineligible for curative surgery or other standard therapies[1][3].

Other names

camsirubicin and pegfilgrastimcamsirubicin plus pegfilgrastim